Abstract
Nitroaromatic antibiotics have a long and controversial history in human and veterinary medicine. This controversy lies behind the presumption of many pharmaceutical companies that nitroaromatic compounds should be filtered from the list of drug-like compounds but stands at odds with the remarkably safe clinical record of use of such compounds. In this review, we will describe the whole-cell structure-activity relationships that have been reported for antimycobacterial nitroimidazoles as well as the available in vivo data supporting efficacy with a particular emphasis on nitroimidazo[2,1-b]oxazines such as PA-824. We will also explore the unique potential of such compounds to shorten the course of tuberculosis therapy by exerting a bactericidal effect on non-replicating bacilli. We will consider the mode of action of such compounds in sensitive organisms and discuss the mechanisms by which resistance may emerge. Finally, we will review the pharmacokinetics, toxicology and laboratory and animal studies linking nitroimidazoles with carcinogenicity and mutagenicity and assess the prospects for the clinical introduction of nitroimidazoles for the treatment of tuberculosis.
Keywords: mycobacterium tuberculosis, nitroimidazole, bioreduction, nitroreductase, persistence, anaerobic metabolism, metronidazole, mutagenicity
Current Pharmaceutical Design
Title: Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Volume: 10 Issue: 26
Author(s): Clifton E. Barry, Helena I.M. Boshoff and Cynthia S. Dowd
Affiliation:
Keywords: mycobacterium tuberculosis, nitroimidazole, bioreduction, nitroreductase, persistence, anaerobic metabolism, metronidazole, mutagenicity
Abstract: Nitroaromatic antibiotics have a long and controversial history in human and veterinary medicine. This controversy lies behind the presumption of many pharmaceutical companies that nitroaromatic compounds should be filtered from the list of drug-like compounds but stands at odds with the remarkably safe clinical record of use of such compounds. In this review, we will describe the whole-cell structure-activity relationships that have been reported for antimycobacterial nitroimidazoles as well as the available in vivo data supporting efficacy with a particular emphasis on nitroimidazo[2,1-b]oxazines such as PA-824. We will also explore the unique potential of such compounds to shorten the course of tuberculosis therapy by exerting a bactericidal effect on non-replicating bacilli. We will consider the mode of action of such compounds in sensitive organisms and discuss the mechanisms by which resistance may emerge. Finally, we will review the pharmacokinetics, toxicology and laboratory and animal studies linking nitroimidazoles with carcinogenicity and mutagenicity and assess the prospects for the clinical introduction of nitroimidazoles for the treatment of tuberculosis.
Export Options
About this article
Cite this article as:
Barry E. Clifton, Boshoff I.M. Helena and Dowd S. Cynthia, Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383214
DOI https://dx.doi.org/10.2174/1381612043383214 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Concise Overview on Recent Advances in Pharmaceutical Aerosols and
their Commercial Applications
Current Materials Science Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis
Current HIV Research Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Circumscribing the Conformational Peptide Epitope Landscape
Current Pharmaceutical Design Di- and Sesquiterpenoids from Cystoseira Genus: Structure, Intra-molecular Transformations and Biological Activity
Mini-Reviews in Medicinal Chemistry Nanoparticles and Immune Cells
Current Pharmaceutical Design In-vitro Antioxidant activity of ‘Aswathy Chooranam’- a Siddha Drug
Current Traditional Medicine Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Methacholin Provocation Test in COPD and Healthy Smokers
Current Respiratory Medicine Reviews Interaction of Host Pattern Recognition Receptors (PRRs) with <i>Mycobacterium Tuberculosis</i> and Ayurvedic Management of Tuberculosis: A Systemic Approach
Infectious Disorders - Drug Targets Synthesis, Antibacterial, Antifungal and Antitubercular Activities of N-Pyrazolylbenzamide Derivatives
Medicinal Chemistry A Pathogenetic Approach to Autoimmune Skin Disease Therapy: Psoriasis and Biological Drugs, Unresolved Issues, and Future Directions
Current Pharmaceutical Design HIV-Infected Patients and Liver Transplantation: Who, When and Why
Current HIV Research Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets Adherence to Antiretroviral Therapy and Tuberculosis Treatment in a Prison of Tehran, Iran
Infectious Disorders - Drug Targets Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Synthesis of Marine Natural Products with Antimalarial Activity
Mini-Reviews in Medicinal Chemistry Pulmonary Drug Delivery: A Role for Polymeric Nanoparticles?
Current Topics in Medicinal Chemistry Screening of Few Epoxides as mt-MAPK Inhibitor Preventing Granuloma Formation to Serve as Tubercular Antidote
Letters in Drug Design & Discovery